{"protocolSection":{"identificationModule":{"nctId":"NCT02730377","orgStudyIdInfo":{"id":"NN2211-4232"},"secondaryIdInfos":[{"id":"2015-002417-29","type":"EUDRACT_NUMBER"},{"id":"U1111-1170-7035","type":"OTHER","domain":"WHO"},{"id":"2015","type":"NIH","link":"https://reporter.nih.gov/quickSearch/2015"}],"organization":{"fullName":"Novo Nordisk A/S","class":"INDUSTRY"},"briefTitle":"Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes","officialTitle":"Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy and Treated in a Primary Care Setting","acronym":"LIRA-PRIME"},"statusModule":{"statusVerifiedDate":"2020-06","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2016-03-28","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2019-08-05","type":"ACTUAL"},"completionDateStruct":{"date":"2019-08-12","type":"ACTUAL"},"studyFirstSubmitDate":"2016-03-23","studyFirstSubmitQcDate":"2016-03-31","studyFirstPostDateStruct":{"date":"2016-04-06","type":"ESTIMATED"},"resultsFirstSubmitDate":"2020-06-16","resultsFirstSubmitQcDate":"2020-06-16","resultsFirstPostDateStruct":{"date":"2020-07-07","type":"ACTUAL"},"lastUpdateSubmitDate":"2020-06-16","lastUpdatePostDateStruct":{"date":"2020-07-07","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Novo Nordisk A/S","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This trial is conducted globally. The aim of the trial is to investigate efficacy in controlling glycaemia with Victoza® (liraglutide) as add-on to metformin background treatment vs. OADs as add-on to metformin background treatment for 104 weeks of treatment in subjects with type 2 diabetes."},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":1991,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Liraglutide 1.8 mg","type":"EXPERIMENTAL","description":"Add-on to metformin","interventionNames":["Drug: liraglutide"]},{"label":"OAD","type":"ACTIVE_COMPARATOR","description":"Add-on to metformin. Treatment with one OAD selected at the discretion of the investigator. Subjects randomised to the OAD arm must remain on the same OAD throughout the trial.","interventionNames":["Drug: alpha-glucosidase inhibitors","Drug: DPP-4 inhibitors","Drug: meglitinides","Drug: SGLT-2 inhibitors","Drug: sulphonylurea","Drug: thiazolidinediones"]}],"interventions":[{"type":"DRUG","name":"liraglutide","description":"Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.","armGroupLabels":["Liraglutide 1.8 mg"]},{"type":"DRUG","name":"alpha-glucosidase inhibitors","description":"Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.","armGroupLabels":["OAD"]},{"type":"DRUG","name":"DPP-4 inhibitors","description":"Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.","armGroupLabels":["OAD"]},{"type":"DRUG","name":"meglitinides","description":"Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.","armGroupLabels":["OAD"]},{"type":"DRUG","name":"SGLT-2 inhibitors","description":"Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.","armGroupLabels":["OAD"]},{"type":"DRUG","name":"sulphonylurea","description":"Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.","armGroupLabels":["OAD"]},{"type":"DRUG","name":"thiazolidinediones","description":"Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.","armGroupLabels":["OAD"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Time to Inadequate Glycaemic Control","description":"Inadequate glycaemic control was defined as glycosylated haemoglobin (HbA1c) of 7.0% (53 mmol/mol) or greater at two consecutive visits after the first 26 weeks of treatment and up to 104 weeks. 25%, median (50%) and 75% percentiles for the cumulative distribution function, are obtained from the Kaplan-Meier survival function. HbA1c was recorded at weeks 38, 52, 65, 78, 91 and 104.","timeFrame":"Weeks 26-104"}],"secondaryOutcomes":[{"measure":"Time to Premature Treatment Discontinuation (for Any Reason Including Inadequate Glycaemic Control)","description":"The time to premature treatment discontinuation (for any reason including inadequate glycaemic control) was analysed and presented using the generalised log rank test. 25%, median (50%) and 75% percentiles for the cumulative distribution function, are obtained from the Kaplan-Meier survival function.","timeFrame":"Weeks 0-104"},{"measure":"Change in HbA1c","description":"Change from baseline (week 0) in HbA1c at week 104 or at premature treatment discontinuation is presented.","timeFrame":"Week 0, week 104/premature treatment discontinuation"},{"measure":"Participants Who Achieve HbA1c ≤6.5% (Yes/No)","description":"Participants who achieved HbA1c ≤6.5% (yes/no) is presented.","timeFrame":"Week 104/Premature treatment discontinuation"},{"measure":"Participants Who Achieve HbA1c ≤7.0% Without Weight Gain","description":"Participants who achieved HbA1c ≤7.0% without weight gain (yes/no) is presented.","timeFrame":"Week 104/Premature treatment discontinuation"},{"measure":"Participants Who Achieve HbA1c ≤7.0% Without Treatment Emergent Severe Hypoglycaemic Episodes or BG Confirmed Symptomatic Hypoglycaemic Episodes","description":"Severe or blood glucose (BG) confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \\<3.1 millimoles per liter (mmol/L) with symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than the day after the last day on trial product. Participants who achieved HbA1c ≤7.0% without treatment emergent severe hypoglycaemic episodes or BG confirmed symptomatic hypoglycaemic episodes (yes/no) is presented.","timeFrame":"Week 104/Premature treatment discontinuation"},{"measure":"Participants Who Achieve HbA1c ≤7.0% Without Weight Gain and no Treatment Emergent Severe Hypoglycaemic Episodes or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes","description":"Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \\<3.1 mmol/L with symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than the day after the last day on trial product. Participants who achieved HbA1c ≤7.0% without weight gain and no treatment emergent severe hypoglycaemic episodes or BG confirmed symptomatic hypoglycaemic episodes (yes/no) is presented.","timeFrame":"Week 104/Premature treatment discontinuation"},{"measure":"Change in Fasting Plasma Glucose (FPG)","description":"Change from baseline (week 0) in FPG at week 104 or at premature treatment discontinuation is presented.","timeFrame":"Week 0, week 104/premature treatment discontinuation"},{"measure":"Change in Body Weight","description":"Change from baseline (week 0) in body weight at week 104 or at premature treatment discontinuation is presented.","timeFrame":"Week 0, week 104/premature treatment discontinuation"},{"measure":"Change in Body Mass Index (BMI)","description":"Change from baseline (week 0) in BMI at week 104 or at premature treatment discontinuation is presented.","timeFrame":"Week 0, week 104/premature treatment discontinuation"},{"measure":"Change in Blood Pressure (Systolic and Diastolic Blood Pressure)","description":"Change from baseline (week 0) in systolic and diastolic blood pressure at week 104 or at premature treatment discontinuation is presented.","timeFrame":"Week 0, week 104/premature treatment discontinuation"},{"measure":"Number of Severe Hypoglycaemic Episodes","description":"Severe hypoglycaemic episodes were defined as episodes that required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Number of severe hypoglycaemic episodes that occured during weeks 0-104 are presented.","timeFrame":"Weeks 0-104"},{"measure":"Number of Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes","description":"Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \\<3.1 mmol/L with symptoms consistent with hypoglycaemia. Number of severe or BG confirmed symptomatic hypoglycaemic episodes that occured during weeks 0-104 are presented.","timeFrame":"Weeks 0-104"},{"measure":"Number of Documented Symptomatic Hypoglycaemic Episodes (ADA)","description":"Documented symptomatic hypoglycaemic were defined as episodes with typical symptoms of hypoglycaemia accompanied by measure plasma glucose concentration \\<= 3.9 mmol/L. Number of documented symptomatic hypoglycaemic episodes that occured during the weeks 0-104 are presented.","timeFrame":"Weeks 0-104"},{"measure":"Number of Serious Adverse Events (SAEs)","description":"A serious adverse event (SAE) was defined as any event that resulted in any of the following: death, life-threatening experience, in-patient hospitalisation or prolongation of existing hospitalisation, persistent or significant disability or incapacity, congenital anomaly or birth defect or suspicion of transmission of infectious agents via the trial product. An SAE was considered as treatment emergent if it had an onset or increase in severity on or after the time of first trial product administration and no later than 7 days after the time of last trial product administration. Number of treatment emergent serious adverse events are presented.","timeFrame":"Weeks 0-105"},{"measure":"Number of AEs Leading to Permanent Discontinuation of Trial Product","description":"An adverse event (AE) was any untoward medical occurrence in a participant who administered a product, and which did not necessarily had a causal relationship with this treatment. An AE was considered as treatment emergent if it had an onset or increase in severity on or after the time of first trial product administration and no later than 7 days after the time of last trial product administration. Number of treatment emergent AEs that led to permanent discontinuation of trial product are presented.","timeFrame":"Weeks 0-105"},{"measure":"Change in Lipids: HDL Cholesterol, LDL-cholesterol, Total Cholesterol, Triglycerides","description":"Change from baseline (week 0) in high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, total cholesterol (TC) and triglycerides (TG) at week 104 or at premature treatment discontinuation is presented.","timeFrame":"Week 0, week 104/premature treatment discontinuation"},{"measure":"Change in Biochemistry- Alanine Aminotransferase (ALAT), Amylase, Aspartate Aminotransferase (ASAT), Lipase","description":"Change from baseline (week 0) in alanine aminotransferase (ALAT), amylase, aspartate aminotransferase (ASAT) and lipase at week 104 or at premature treatment discontinuation is presented.","timeFrame":"Week 0, week 104/premature treatment discontinuation"},{"measure":"Change in Biochemistry- Creatinine, Total Bilirubin","description":"Change from baseline (week 0) in creatinine and total bilirubin (TB) at week 104 or at premature treatment discontinuation is presented.","timeFrame":"Week 0, week 104/premature treatment discontinuation"},{"measure":"Change in Biochemistry- Estimated Glomerular Filtration Rate (eGFR) Serum","description":"The estimated GFR was derived from serum creatinine using the MDRD (Modification of diet in renal disease) formula. eGFR was measured as milliliter per min per specific surface area (mL/min/SSA).","timeFrame":"Week 0, week 104/premature treatment discontinuation"},{"measure":"Change in Potassium","description":"Change from baseline (week 0) in potassium at week 104 or at premature treatment discontinuation is presented.","timeFrame":"Week 0, week 104/premature treatment discontinuation"},{"measure":"Change in Haemoglobin","description":"Change from baseline (week 0) in haemoglobin at week 104 or at premature treatment discontinuation is presented.","timeFrame":"Week 0, week 104/premature treatment discontinuation"},{"measure":"Change in Pulse","description":"Change from baseline (week 0) in pulse at week 104 or at premature treatment discontinuation is presented.","timeFrame":"Week 0, week 104/premature treatment discontinuation"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria: - Male or female at least 18 years of age at the time of signing informed consent - Subjects diagnosed (clinically) with type 2 diabetes equal to or above 90 days prior to the screening visit - Stable daily dose of metformin as monotherapy equal to or above 1500 mg or maximum tolerated dose within 60 days prior to the screening visit - HbA1c 7.5-9.0% (59-75 mmol/mol) (both inclusive) and measured within the last 90 days prior to the screening visit Exclusion Criteria: - Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive methods (adequate contraceptive measures as required by local regulation or practice) - Treatment with any medication for the indication of diabetes other than metformin in a period of 60 days before the screening visit. An exception is short-term treatment (below or equal to 7 days in total) with insulin in connection with intercurrent illness - Receipt of any investigational medicinal product within 30 days before the screening visit - Any disorder, which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Novo Nordisk Investigational Site","city":"Birmingham","state":"Alabama","zip":"35211","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"Novo Nordisk Investigational Site","city":"Haleyville","state":"Alabama","zip":"35565-1719","country":"United States","geoPoint":{"lat":34.22649,"lon":-87.62141}},{"facility":"Novo Nordisk Investigational Site","city":"Tuscumbia","state":"Alabama","zip":"35674","country":"United States","geoPoint":{"lat":34.7312,"lon":-87.70253}},{"facility":"Novo Nordisk Investigational Site","city":"Fountain Hills","state":"Arizona","zip":"85268","country":"United States","geoPoint":{"lat":33.61171,"lon":-111.71736}},{"facility":"Novo Nordisk Investigational Site","city":"Phoenix","state":"Arizona","zip":"85018","country":"United States","geoPoint":{"lat":33.44838,"lon":-112.07404}},{"facility":"Novo Nordisk Investigational Site","city":"Phoenix","state":"Arizona","zip":"85037","country":"United States","geoPoint":{"lat":33.44838,"lon":-112.07404}},{"facility":"Novo Nordisk Investigational Site","city":"Phoenix","state":"Arizona","zip":"85050","country":"United States","geoPoint":{"lat":33.44838,"lon":-112.07404}},{"facility":"Novo Nordisk Investigational Site","city":"Tempe","state":"Arizona","zip":"85283","country":"United States","geoPoint":{"lat":33.41477,"lon":-111.90931}},{"facility":"Novo Nordisk Investigational Site","city":"Tucson","state":"Arizona","zip":"85741","country":"United States","geoPoint":{"lat":32.22174,"lon":-110.92648}},{"facility":"Novo Nordisk Investigational Site","city":"Harrisburg","state":"Arkansas","zip":"72432-1132","country":"United States","geoPoint":{"lat":35.56425,"lon":-90.71678}},{"facility":"Novo Nordisk Investigational Site","city":"Little Rock","state":"Arkansas","zip":"72212","country":"United States","geoPoint":{"lat":34.74648,"lon":-92.28959}},{"facility":"Novo Nordisk Investigational Site","city":"North Little Rock","state":"Arkansas","zip":"72117","country":"United States","geoPoint":{"lat":34.76954,"lon":-92.26709}},{"facility":"Novo Nordisk Investigational Site","city":"Searcy","state":"Arkansas","zip":"72143","country":"United States","geoPoint":{"lat":35.25064,"lon":-91.73625}},{"facility":"Novo Nordisk Investigational Site","city":"Alhambra","state":"California","zip":"91801","country":"United States","geoPoint":{"lat":34.09529,"lon":-118.12701}},{"facility":"Novo Nordisk Investigational Site","city":"Buena Park","state":"California","zip":"90620","country":"United States","geoPoint":{"lat":33.86751,"lon":-117.99812}},{"facility":"Novo Nordisk Investigational Site","city":"Carlsbad","state":"California","zip":"92008","country":"United States","geoPoint":{"lat":33.15809,"lon":-117.35059}},{"facility":"Novo Nordisk Investigational Site","city":"Coronado","state":"California","zip":"92118","country":"United States","geoPoint":{"lat":32.68589,"lon":-117.18309}},{"facility":"Novo Nordisk Investigational Site","city":"Costa Mesa","state":"California","zip":"92627","country":"United States","geoPoint":{"lat":33.64113,"lon":-117.91867}},{"facility":"Novo Nordisk Investigational Site","city":"Elk Grove","state":"California","zip":"95758","country":"United States","geoPoint":{"lat":38.4088,"lon":-121.37162}},{"facility":"Novo Nordisk Investigational Site","city":"Encinitas","state":"California","zip":"92024","country":"United States","geoPoint":{"lat":33.03699,"lon":-117.29198}},{"facility":"Novo Nordisk Investigational Site","city":"Huntington Beach","state":"California","zip":"92646","country":"United States","geoPoint":{"lat":33.6603,"lon":-117.99923}},{"facility":"Novo Nordisk Investigational Site","city":"La Mirada","state":"California","zip":"90638","country":"United States","geoPoint":{"lat":33.91724,"lon":-118.01201}},{"facility":"Novo Nordisk Investigational Site","city":"Lancaster","state":"California","zip":"93534","country":"United States","geoPoint":{"lat":34.69804,"lon":-118.13674}},{"facility":"Novo Nordisk Investigational Site","city":"Lomita","state":"California","zip":"90717","country":"United States","geoPoint":{"lat":33.79224,"lon":-118.31507}},{"facility":"Novo Nordisk Investigational Site","city":"Montclair","state":"California","zip":"91763","country":"United States","geoPoint":{"lat":34.07751,"lon":-117.68978}},{"facility":"Novo Nordisk Investigational Site","city":"Northridge","state":"California","zip":"91325","country":"United States","geoPoint":{"lat":34.22834,"lon":-118.53675}},{"facility":"Novo Nordisk Investigational Site","city":"Oxnard","state":"California","zip":"93030","country":"United States","geoPoint":{"lat":34.1975,"lon":-119.17705}},{"facility":"Novo Nordisk Investigational Site","city":"Rancho Cucamonga","state":"California","zip":"91730-3063","country":"United States","geoPoint":{"lat":34.1064,"lon":-117.59311}},{"facility":"Novo Nordisk Investigational Site","city":"Riverside","state":"California","zip":"92506","country":"United States","geoPoint":{"lat":33.95335,"lon":-117.39616}},{"facility":"Novo Nordisk Investigational Site","city":"San Diego","state":"California","zip":"92111","country":"United States","geoPoint":{"lat":32.71571,"lon":-117.16472}},{"facility":"Novo Nordisk Investigational Site","city":"San Diego","state":"California","zip":"92120","country":"United States","geoPoint":{"lat":32.71571,"lon":-117.16472}},{"facility":"Novo Nordisk Investigational Site","city":"San Ramon","state":"California","zip":"94582","country":"United States","geoPoint":{"lat":37.77993,"lon":-121.97802}},{"facility":"Novo Nordisk Investigational Site","city":"Tustin","state":"California","zip":"92780","country":"United States","geoPoint":{"lat":33.74585,"lon":-117.82617}},{"facility":"Novo Nordisk Investigational Site","city":"Westminster","state":"California","zip":"92683","country":"United States","geoPoint":{"lat":33.75918,"lon":-118.00673}},{"facility":"Novo Nordisk Investigational Site","city":"Centennial","state":"Colorado","zip":"80012","country":"United States","geoPoint":{"lat":39.57916,"lon":-104.87692}},{"facility":"Novo Nordisk Investigational Site","city":"Centennial","state":"Colorado","zip":"80112","country":"United States","geoPoint":{"lat":39.57916,"lon":-104.87692}},{"facility":"Novo Nordisk Investigational Site","city":"Colorado Springs","state":"Colorado","zip":"80906","country":"United States","geoPoint":{"lat":38.83388,"lon":-104.82136}},{"facility":"Novo Nordisk Investigational Site","city":"Golden","state":"Colorado","zip":"80401","country":"United States","geoPoint":{"lat":39.75554,"lon":-105.2211}},{"facility":"Novo Nordisk Investigational Site","city":"Monument","state":"Colorado","zip":"80132","country":"United States","geoPoint":{"lat":39.09166,"lon":-104.87276}},{"facility":"Novo Nordisk Investigational Site","city":"Chiefland","state":"Florida","zip":"32626","country":"United States","geoPoint":{"lat":29.47496,"lon":-82.85984}},{"facility":"Novo Nordisk Investigational Site","city":"Clearwater","state":"Florida","zip":"33756","country":"United States","geoPoint":{"lat":27.96585,"lon":-82.8001}},{"facility":"Novo Nordisk Investigational Site","city":"Fort Lauderdale","state":"Florida","zip":"33316","country":"United States","geoPoint":{"lat":26.12231,"lon":-80.14338}},{"facility":"Novo Nordisk Investigational Site","city":"Hollywood","state":"Florida","zip":"33024","country":"United States","geoPoint":{"lat":26.0112,"lon":-80.14949}},{"facility":"Novo Nordisk Investigational Site","city":"Jacksonville","state":"Florida","zip":"32205","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"Novo Nordisk Investigational Site","city":"Kissimmee","state":"Florida","zip":"34741","country":"United States","geoPoint":{"lat":28.30468,"lon":-81.41667}},{"facility":"Novo Nordisk Investigational Site","city":"Miami","state":"Florida","zip":"33174","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Novo Nordisk Investigational Site","city":"Miami","state":"Florida","zip":"33175","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Novo Nordisk Investigational Site","city":"Ocala","state":"Florida","zip":"34470","country":"United States","geoPoint":{"lat":29.1872,"lon":-82.14009}},{"facility":"Novo Nordisk Investigational Site","city":"Ocoee","state":"Florida","zip":"34761","country":"United States","geoPoint":{"lat":28.56917,"lon":-81.54396}},{"facility":"Novo Nordisk Investigational Site","city":"Orlando","state":"Florida","zip":"32819","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"Novo Nordisk Investigational Site","city":"Ormond Beach","state":"Florida","zip":"32174-6302","country":"United States","geoPoint":{"lat":29.28581,"lon":-81.05589}},{"facility":"Novo Nordisk Investigational Site","city":"Oviedo","state":"Florida","zip":"32765","country":"United States","geoPoint":{"lat":28.67,"lon":-81.20812}},{"facility":"Novo Nordisk Investigational Site","city":"Palm Harbor","state":"Florida","zip":"34684-3609","country":"United States","geoPoint":{"lat":28.07807,"lon":-82.76371}},{"facility":"Novo Nordisk Investigational Site","city":"Pembroke Pines","state":"Florida","zip":"33027","country":"United States","geoPoint":{"lat":26.00315,"lon":-80.22394}},{"facility":"Novo Nordisk Investigational Site","city":"Seminole","state":"Florida","zip":"33773","country":"United States","geoPoint":{"lat":27.83975,"lon":-82.79121}},{"facility":"Novo Nordisk Investigational Site","city":"St. Petersburg","state":"Florida","zip":"33713","country":"United States","geoPoint":{"lat":27.77086,"lon":-82.67927}},{"facility":"Novo Nordisk Investigational Site","city":"Bainbridge","state":"Georgia","zip":"39819","country":"United States","geoPoint":{"lat":30.9038,"lon":-84.57547}},{"facility":"Novo Nordisk Investigational Site","city":"Conyers","state":"Georgia","zip":"30094-5965","country":"United States","geoPoint":{"lat":33.66761,"lon":-84.01769}},{"facility":"Novo Nordisk Investigational Site","city":"Perry","state":"Georgia","zip":"31069","country":"United States","geoPoint":{"lat":32.45821,"lon":-83.73157}},{"facility":"Novo Nordisk Investigational Site","city":"Statesboro","state":"Georgia","zip":"30461","country":"United States","geoPoint":{"lat":32.44879,"lon":-81.78317}},{"facility":"Novo Nordisk Investigational Site","city":"Suwanee","state":"Georgia","zip":"30024","country":"United States","geoPoint":{"lat":34.05149,"lon":-84.0713}},{"facility":"Novo Nordisk Investigational Site","city":"Woodstock","state":"Georgia","zip":"30189-4255","country":"United States","geoPoint":{"lat":34.10149,"lon":-84.51938}},{"facility":"Novo Nordisk Investigational Site","city":"Meridian","state":"Idaho","zip":"83646","country":"United States","geoPoint":{"lat":43.61211,"lon":-116.39151}},{"facility":"Novo Nordisk Investigational Site","city":"Aurora","state":"Illinois","zip":"60506","country":"United States","geoPoint":{"lat":41.76058,"lon":-88.32007}},{"facility":"Novo Nordisk Investigational Site","city":"Chicago","state":"Illinois","zip":"60616","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Novo Nordisk Investigational Site","city":"Gillespie","state":"Illinois","zip":"62033","country":"United States","geoPoint":{"lat":39.12977,"lon":-89.81954}},{"facility":"Novo Nordisk Investigational Site","city":"Wauconda","state":"Illinois","zip":"60084","country":"United States","geoPoint":{"lat":42.25891,"lon":-88.13925}},{"facility":"Novo Nordisk Investigational Site","city":"Avon","state":"Indiana","zip":"46123","country":"United States","geoPoint":{"lat":39.76282,"lon":-86.39972}},{"facility":"Novo Nordisk Investigational Site","city":"Evansville","state":"Indiana","zip":"47714","country":"United States","geoPoint":{"lat":37.97476,"lon":-87.55585}},{"facility":"Novo Nordisk Investigational Site","city":"Greenfield","state":"Indiana","zip":"46140","country":"United States","geoPoint":{"lat":39.78504,"lon":-85.76942}},{"facility":"Novo Nordisk Investigational Site","city":"Muncie","state":"Indiana","zip":"47304","country":"United States","geoPoint":{"lat":40.19338,"lon":-85.38636}},{"facility":"Novo Nordisk Investigational Site","city":"Newton","state":"Kansas","zip":"67114","country":"United States","geoPoint":{"lat":38.04668,"lon":-97.34504}},{"facility":"Novo Nordisk Investigational Site","city":"Park City","state":"Kansas","zip":"67219","country":"United States","geoPoint":{"lat":37.80001,"lon":-97.31838}},{"facility":"Novo Nordisk Investigational Site","city":"Wichita","state":"Kansas","zip":"67205","country":"United States","geoPoint":{"lat":37.69224,"lon":-97.33754}},{"facility":"Novo Nordisk Investigational Site","city":"Lexington","state":"Kentucky","zip":"40503","country":"United States","geoPoint":{"lat":37.98869,"lon":-84.47772}},{"facility":"Novo Nordisk Investigational Site","city":"Natchitoches","state":"Louisiana","zip":"71457-5881","country":"United States","geoPoint":{"lat":31.76072,"lon":-93.08627}},{"facility":"Novo Nordisk Investigational Site","city":"Shreveport","state":"Louisiana","zip":"71105","country":"United States","geoPoint":{"lat":32.52515,"lon":-93.75018}},{"facility":"Novo Nordisk Investigational Site","city":"Sunset","state":"Louisiana","zip":"70584","country":"United States","geoPoint":{"lat":30.41131,"lon":-92.06845}},{"facility":"Novo Nordisk Investigational Site","city":"Elkridge","state":"Maryland","zip":"21075-6437","country":"United States","geoPoint":{"lat":39.21261,"lon":-76.71358}},{"facility":"Novo Nordisk Investigational Site","city":"Oxon Hill","state":"Maryland","zip":"20745","country":"United States","geoPoint":{"lat":38.80345,"lon":-76.9897}},{"facility":"Novo Nordisk Investigational Site","city":"Buckley","state":"Michigan","zip":"49620","country":"United States","geoPoint":{"lat":44.50445,"lon":-85.67701}},{"facility":"Novo Nordisk Investigational Site","city":"Rochester","state":"Michigan","zip":"48307","country":"United States","geoPoint":{"lat":42.68059,"lon":-83.13382}},{"facility":"Novo Nordisk Investigational Site","city":"Sterling Heights","state":"Michigan","zip":"48310-3503","country":"United States","geoPoint":{"lat":42.58031,"lon":-83.0302}},{"facility":"Novo Nordisk Investigational Site","city":"Troy","state":"Michigan","zip":"48098","country":"United States","geoPoint":{"lat":42.60559,"lon":-83.14993}},{"facility":"Novo Nordisk Investigational Site","city":"Belzoni","state":"Mississippi","zip":"39038","country":"United States","geoPoint":{"lat":33.18429,"lon":-90.48926}},{"facility":"Novo Nordisk Investigational Site","city":"Port Gibson","state":"Mississippi","zip":"39150","country":"United States","geoPoint":{"lat":31.96099,"lon":-90.98399}},{"facility":"Novo Nordisk Investigational Site","city":"Butte","state":"Montana","zip":"59701","country":"United States","geoPoint":{"lat":46.00382,"lon":-112.53474}},{"facility":"Novo Nordisk Investigational Site","city":"Missoula","state":"Montana","zip":"59808","country":"United States","geoPoint":{"lat":46.87215,"lon":-113.994}},{"facility":"Novo Nordisk Investigational Site","city":"Fremont","state":"Nebraska","zip":"68025","country":"United States","geoPoint":{"lat":41.43333,"lon":-96.49808}},{"facility":"Novo Nordisk Investigational Site","city":"Omaha","state":"Nebraska","zip":"68144","country":"United States","geoPoint":{"lat":41.25626,"lon":-95.94043}},{"facility":"Novo Nordisk Investigational Site","city":"Las Vegas","state":"Nevada","zip":"89118","country":"United States","geoPoint":{"lat":36.17497,"lon":-115.13722}},{"facility":"Novo Nordisk Investigational Site","city":"Albuquerque","state":"New Mexico","zip":"87102","country":"United States","geoPoint":{"lat":35.08449,"lon":-106.65114}},{"facility":"Novo Nordisk Investigational Site","city":"Albuquerque","state":"New Mexico","zip":"87108","country":"United States","geoPoint":{"lat":35.08449,"lon":-106.65114}},{"facility":"Novo Nordisk Investigational Site","city":"Brooklyn","state":"New York","zip":"11215","country":"United States","geoPoint":{"lat":40.6501,"lon":-73.94958}},{"facility":"Novo Nordisk Investigational Site","city":"New Windsor","state":"New York","zip":"12533","country":"United States","geoPoint":{"lat":41.47676,"lon":-74.02375}},{"facility":"Novo Nordisk Investigational Site","city":"North Massapequa","state":"New York","zip":"11758-1802","country":"United States","geoPoint":{"lat":40.70093,"lon":-73.46207}},{"facility":"Novo Nordisk Investigational Site","city":"Westfield","state":"New York","zip":"14787","country":"United States","geoPoint":{"lat":42.32228,"lon":-79.5781}},{"facility":"Novo Nordisk Investigational Site","city":"Asheboro","state":"North Carolina","zip":"27203","country":"United States","geoPoint":{"lat":35.70791,"lon":-79.81364}},{"facility":"Novo Nordisk Investigational Site","city":"Burlington","state":"North Carolina","zip":"27215","country":"United States","geoPoint":{"lat":36.09569,"lon":-79.4378}},{"facility":"Novo Nordisk Investigational Site","city":"Charlotte","state":"North Carolina","zip":"28210","country":"United States","geoPoint":{"lat":35.22709,"lon":-80.84313}},{"facility":"Novo Nordisk Investigational Site","city":"Charlotte","state":"North Carolina","zip":"28277-6594","country":"United States","geoPoint":{"lat":35.22709,"lon":-80.84313}},{"facility":"Novo Nordisk Investigational Site","city":"Charlotte","state":"North Carolina","zip":"28277","country":"United States","geoPoint":{"lat":35.22709,"lon":-80.84313}},{"facility":"Novo Nordisk Investigational Site","city":"Elizabeth City","state":"North Carolina","zip":"27909","country":"United States","geoPoint":{"lat":36.2946,"lon":-76.25105}},{"facility":"Novo Nordisk Investigational Site","city":"Garner","state":"North Carolina","zip":"27529","country":"United States","geoPoint":{"lat":35.71126,"lon":-78.61417}},{"facility":"Novo Nordisk Investigational Site","city":"Mooresville","state":"North Carolina","zip":"28117","country":"United States","geoPoint":{"lat":35.58486,"lon":-80.81007}},{"facility":"Novo Nordisk Investigational Site","city":"Morganton","state":"North Carolina","zip":"28655","country":"United States","geoPoint":{"lat":35.74541,"lon":-81.68482}},{"facility":"Novo Nordisk Investigational Site","city":"Whiteville","state":"North Carolina","zip":"28472","country":"United States","geoPoint":{"lat":34.33878,"lon":-78.70307}},{"facility":"Novo Nordisk Investigational Site","city":"Fargo","state":"North Dakota","zip":"58104","country":"United States","geoPoint":{"lat":46.87719,"lon":-96.7898}},{"facility":"Novo Nordisk Investigational Site","city":"Columbus","state":"Ohio","zip":"43213","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"Novo Nordisk Investigational Site","city":"Dayton","state":"Ohio","zip":"45406","country":"United States","geoPoint":{"lat":39.75895,"lon":-84.19161}},{"facility":"Novo Nordisk Investigational Site","city":"Franklin","state":"Ohio","zip":"45005","country":"United States","geoPoint":{"lat":39.55895,"lon":-84.30411}},{"facility":"Novo Nordisk Investigational Site","city":"Mason","state":"Ohio","zip":"45040-6815","country":"United States","geoPoint":{"lat":39.36006,"lon":-84.30994}},{"facility":"Novo Nordisk Investigational Site","city":"Toledo","state":"Ohio","zip":"43623","country":"United States","geoPoint":{"lat":41.66394,"lon":-83.55521}},{"facility":"Novo Nordisk Investigational Site","city":"Wadsworth","state":"Ohio","zip":"44281","country":"United States","geoPoint":{"lat":41.02561,"lon":-81.72985}},{"facility":"Novo Nordisk Investigational Site","city":"Edmond","state":"Oklahoma","zip":"73034","country":"United States","geoPoint":{"lat":35.65283,"lon":-97.4781}},{"facility":"Novo Nordisk Investigational Site","city":"Oklahoma City","state":"Oklahoma","zip":"73112","country":"United States","geoPoint":{"lat":35.46756,"lon":-97.51643}},{"facility":"Novo Nordisk Investigational Site","city":"Oklahoma City","state":"Oklahoma","zip":"73162-4704","country":"United States","geoPoint":{"lat":35.46756,"lon":-97.51643}},{"facility":"Novo Nordisk Investigational Site","city":"Beaver","state":"Pennsylvania","zip":"15009","country":"United States","geoPoint":{"lat":40.69534,"lon":-80.30478}},{"facility":"Novo Nordisk Investigational Site","city":"Fleetwood","state":"Pennsylvania","zip":"19522","country":"United States","geoPoint":{"lat":40.45398,"lon":-75.81798}},{"facility":"Novo Nordisk Investigational Site","city":"Harleysville","state":"Pennsylvania","zip":"19438","country":"United States","geoPoint":{"lat":40.27955,"lon":-75.38712}},{"facility":"Novo Nordisk Investigational Site","city":"Jersey Shore","state":"Pennsylvania","zip":"17740","country":"United States","geoPoint":{"lat":41.20202,"lon":-77.26442}},{"facility":"Novo Nordisk Investigational Site","city":"Lansdale","state":"Pennsylvania","zip":"19446-1002","country":"United States","geoPoint":{"lat":40.2415,"lon":-75.28379}},{"facility":"Novo Nordisk Investigational Site","city":"Levittown","state":"Pennsylvania","zip":"19056-2404","country":"United States","geoPoint":{"lat":40.15511,"lon":-74.82877}},{"facility":"Novo Nordisk Investigational Site","city":"Levittown","state":"Pennsylvania","zip":"19056","country":"United States","geoPoint":{"lat":40.15511,"lon":-74.82877}},{"facility":"Novo Nordisk Investigational Site","city":"McMurray","state":"Pennsylvania","zip":"15317","country":"United States","geoPoint":{"lat":40.27785,"lon":-80.08394}},{"facility":"Novo Nordisk Investigational Site","city":"Philadelphia","state":"Pennsylvania","zip":"19114","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"Novo Nordisk Investigational Site","city":"Pittsburgh","state":"Pennsylvania","zip":"15236","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"facility":"Novo Nordisk Investigational Site","city":"Pittsburgh","state":"Pennsylvania","zip":"15243","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"facility":"Novo Nordisk Investigational Site","city":"Smithfield","state":"Pennsylvania","zip":"15478","country":"United States","geoPoint":{"lat":39.80313,"lon":-79.80783}},{"facility":"Novo Nordisk Investigational Site","city":"Uniontown","state":"Pennsylvania","zip":"15401","country":"United States","geoPoint":{"lat":39.90008,"lon":-79.71643}},{"facility":"Novo Nordisk Investigational Site","city":"Providence","state":"Rhode Island","zip":"02908","country":"United States","geoPoint":{"lat":41.82399,"lon":-71.41283}},{"facility":"Novo Nordisk Investigational Site","city":"Anderson","state":"South Carolina","zip":"29621","country":"United States","geoPoint":{"lat":34.50344,"lon":-82.65013}},{"facility":"Novo Nordisk Investigational Site","city":"Columbia","state":"South Carolina","zip":"29223","country":"United States","geoPoint":{"lat":34.00071,"lon":-81.03481}},{"facility":"Novo Nordisk Investigational Site","city":"Greer","state":"South Carolina","zip":"29651","country":"United States","geoPoint":{"lat":34.93873,"lon":-82.22706}},{"facility":"Novo Nordisk Investigational Site","city":"Old Point Station","state":"South Carolina","zip":"29707","country":"United States","geoPoint":{"lat":34.95987,"lon":-81.04869}},{"facility":"Novo Nordisk Investigational Site","city":"Pelzer","state":"South Carolina","zip":"29669","country":"United States","geoPoint":{"lat":34.64234,"lon":-82.45596}},{"facility":"Novo Nordisk Investigational Site","city":"Simpsonville","state":"South Carolina","zip":"29681","country":"United States","geoPoint":{"lat":34.73706,"lon":-82.25428}},{"facility":"Novo Nordisk Investigational Site","city":"Rapid City","state":"South Dakota","zip":"57702","country":"United States","geoPoint":{"lat":44.08054,"lon":-103.23101}},{"facility":"Novo Nordisk Investigational Site","city":"Athens","state":"Tennessee","zip":"37303","country":"United States","geoPoint":{"lat":35.44285,"lon":-84.59299}},{"facility":"Novo Nordisk Investigational Site","city":"Chattanooga","state":"Tennessee","zip":"37404","country":"United States","geoPoint":{"lat":35.04563,"lon":-85.30968}},{"facility":"Novo Nordisk Investigational Site","city":"Humboldt","state":"Tennessee","zip":"38343","country":"United States","geoPoint":{"lat":35.81979,"lon":-88.9159}},{"facility":"Novo Nordisk Investigational Site","city":"Kingsport","state":"Tennessee","zip":"37660","country":"United States","geoPoint":{"lat":36.54843,"lon":-82.56182}},{"facility":"Novo Nordisk Investigational Site","city":"Tullahoma","state":"Tennessee","zip":"37388","country":"United States","geoPoint":{"lat":35.36202,"lon":-86.20943}},{"facility":"Novo Nordisk Investigational Site","city":"Arlington","state":"Texas","zip":"76014-2010","country":"United States","geoPoint":{"lat":32.73569,"lon":-97.10807}},{"facility":"Novo Nordisk Investigational Site","city":"Arlington","state":"Texas","zip":"76015","country":"United States","geoPoint":{"lat":32.73569,"lon":-97.10807}},{"facility":"Novo Nordisk Investigational Site","city":"Carrollton","state":"Texas","zip":"75010","country":"United States","geoPoint":{"lat":32.95373,"lon":-96.89028}},{"facility":"Novo Nordisk Investigational Site","city":"Corpus Christi","state":"Texas","zip":"78404","country":"United States","geoPoint":{"lat":27.80058,"lon":-97.39638}},{"facility":"Novo Nordisk Investigational Site","city":"Corpus Christi","state":"Texas","zip":"78413","country":"United States","geoPoint":{"lat":27.80058,"lon":-97.39638}},{"facility":"Novo Nordisk Investigational Site","city":"Dallas","state":"Texas","zip":"75251","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Novo Nordisk Investigational Site","city":"Fort Worth","state":"Texas","zip":"76164","country":"United States","geoPoint":{"lat":32.72541,"lon":-97.32085}},{"facility":"Novo Nordisk Investigational Site","city":"Georgetown","state":"Texas","zip":"78626","country":"United States","geoPoint":{"lat":30.63269,"lon":-97.67723}},{"facility":"Novo Nordisk Investigational Site","city":"Gonzales","state":"Texas","zip":"78629","country":"United States","geoPoint":{"lat":29.50163,"lon":-97.45249}},{"facility":"Novo Nordisk Investigational Site","city":"Houston","state":"Texas","zip":"77024","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Novo Nordisk Investigational Site","city":"Houston","state":"Texas","zip":"77025-1669","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Novo Nordisk Investigational Site","city":"Houston","state":"Texas","zip":"77061","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Novo Nordisk Investigational Site","city":"Houston","state":"Texas","zip":"77074","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Novo Nordisk Investigational Site","city":"Houston","state":"Texas","zip":"77079","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Novo Nordisk Investigational Site","city":"Houston","state":"Texas","zip":"77081","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Novo Nordisk Investigational Site","city":"Irving","state":"Texas","zip":"75061-2210","country":"United States","geoPoint":{"lat":32.81402,"lon":-96.94889}},{"facility":"Novo Nordisk Investigational Site","city":"Kerrville","state":"Texas","zip":"78028","country":"United States","geoPoint":{"lat":30.04743,"lon":-99.14032}},{"facility":"Novo Nordisk Investigational Site","city":"Killeen","state":"Texas","zip":"76543","country":"United States","geoPoint":{"lat":31.11712,"lon":-97.7278}},{"facility":"Novo Nordisk Investigational Site","city":"Longview","state":"Texas","zip":"75605","country":"United States","geoPoint":{"lat":32.5007,"lon":-94.74049}},{"facility":"Novo Nordisk Investigational Site","city":"Missouri City","state":"Texas","zip":"77459","country":"United States","geoPoint":{"lat":29.61857,"lon":-95.53772}},{"facility":"Novo Nordisk Investigational Site","city":"New Braunfels","state":"Texas","zip":"78130","country":"United States","geoPoint":{"lat":29.703,"lon":-98.12445}},{"facility":"Novo Nordisk Investigational Site","city":"San Antonio","state":"Texas","zip":"78240","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"Novo Nordisk Investigational Site","city":"Splendora","state":"Texas","zip":"77372","country":"United States","geoPoint":{"lat":30.23299,"lon":-95.16104}},{"facility":"Novo Nordisk Investigational Site","city":"Sugar Land","state":"Texas","zip":"77478","country":"United States","geoPoint":{"lat":29.61968,"lon":-95.63495}},{"facility":"Novo Nordisk Investigational Site","city":"Sugar Land","state":"Texas","zip":"77479","country":"United States","geoPoint":{"lat":29.61968,"lon":-95.63495}},{"facility":"Novo Nordisk Investigational Site","city":"Waco","state":"Texas","zip":"76710","country":"United States","geoPoint":{"lat":31.54933,"lon":-97.14667}},{"facility":"Novo Nordisk Investigational Site","city":"Bountiful","state":"Utah","zip":"84010","country":"United States","geoPoint":{"lat":40.88939,"lon":-111.88077}},{"facility":"Novo Nordisk Investigational Site","city":"St. George","state":"Utah","zip":"84790","country":"United States","geoPoint":{"lat":37.10415,"lon":-113.58412}},{"facility":"Novo Nordisk Investigational Site","city":"Danville","state":"Virginia","zip":"24541","country":"United States","geoPoint":{"lat":36.58597,"lon":-79.39502}},{"facility":"Novo Nordisk Investigational Site","city":"Gloucester Courthouse","state":"Virginia","zip":"23061","country":"United States","geoPoint":{"lat":37.40986,"lon":-76.52662}},{"facility":"Novo Nordisk Investigational Site","city":"Norfolk","state":"Virginia","zip":"23510-2015","country":"United States","geoPoint":{"lat":36.84681,"lon":-76.28522}},{"facility":"Novo Nordisk Investigational Site","city":"Richmond","state":"Virginia","zip":"23219","country":"United States","geoPoint":{"lat":37.55376,"lon":-77.46026}},{"facility":"Novo Nordisk Investigational Site","city":"Virginia Beach","state":"Virginia","zip":"23454","country":"United States","geoPoint":{"lat":36.85293,"lon":-75.97799}},{"facility":"Novo Nordisk Investigational Site","city":"Bellevue","state":"Washington","zip":"98004-4604","country":"United States","geoPoint":{"lat":47.61038,"lon":-122.20068}},{"facility":"Novo Nordisk Investigational Site","city":"Spokane","state":"Washington","zip":"99216-1557","country":"United States","geoPoint":{"lat":47.65966,"lon":-117.42908}},{"facility":"Novo Nordisk Investigational Site","city":"Walla Walla","state":"Washington","zip":"99362-4445","country":"United States","geoPoint":{"lat":46.06458,"lon":-118.34302}},{"facility":"Novo Nordisk Investigational Site","city":"Surrey","state":"British Columbia","zip":"V3Z 2N6","country":"Canada","geoPoint":{"lat":49.10635,"lon":-122.82509}},{"facility":"Novo Nordisk Investigational Site","city":"Mount Pearl","state":"Newfoundland and Labrador","zip":"A1N 1W7","country":"Canada","geoPoint":{"lat":47.51659,"lon":-52.78135}},{"facility":"Novo Nordisk Investigational Site","city":"Truro","state":"Nova Scotia","zip":"B2N 1L2","country":"Canada","geoPoint":{"lat":45.36685,"lon":-63.26538}},{"facility":"Novo Nordisk Investigational Site","city":"Hamilton","state":"Ontario","zip":"L8M 1K7","country":"Canada","geoPoint":{"lat":43.25011,"lon":-79.84963}},{"facility":"Novo Nordisk Investigational Site","city":"Sarnia","state":"Ontario","zip":"N7T 4X3","country":"Canada","geoPoint":{"lat":42.97866,"lon":-82.40407}},{"facility":"Novo Nordisk Investigational Site","city":"Strathroy","state":"Ontario","zip":"N7G 1Y7","country":"Canada","geoPoint":{"lat":42.9551,"lon":-81.62232}},{"facility":"Novo Nordisk Investigational Site","city":"Toronto","state":"Ontario","zip":"M3J 1N2","country":"Canada","geoPoint":{"lat":43.70643,"lon":-79.39864}},{"facility":"Novo Nordisk Investigational Site","city":"Toronto","state":"Ontario","zip":"M9V 4B4","country":"Canada","geoPoint":{"lat":43.70643,"lon":-79.39864}},{"facility":"Novo Nordisk Investigational Site","city":"Waterloo","state":"Ontario","zip":"N2J 1C4","country":"Canada","geoPoint":{"lat":43.4668,"lon":-80.51639}},{"facility":"Novo Nordisk Investigational Site","city":"Montreal","state":"Quebec","zip":"H4N 2W2","country":"Canada","geoPoint":{"lat":45.50884,"lon":-73.58781}},{"facility":"Novo Nordisk Investigational Site","city":"Saint-Marc-des-Carrieres","state":"Quebec","zip":"G0A 4B0","country":"Canada","geoPoint":{"lat":46.68335,"lon":-72.0491}},{"facility":"Novo Nordisk Investigational Site","city":"Québec","zip":"G1G 3Y8","country":"Canada","geoPoint":{"lat":46.81228,"lon":-71.21454}},{"facility":"Novo Nordisk Investigational Site","city":"Bogotá","zip":"110221","country":"Colombia","geoPoint":{"lat":4.60971,"lon":-74.08175}},{"facility":"Novo Nordisk Investigational Site","city":"Bogotá","zip":"111211","country":"Colombia","geoPoint":{"lat":4.60971,"lon":-74.08175}},{"facility":"Novo Nordisk Investigational Site","city":"Medellín","country":"Colombia","geoPoint":{"lat":6.245,"lon":-75.57151}},{"facility":"Novo Nordisk Investigational Site","city":"Bangalore","state":"Karnataka","zip":"560 017","country":"India","geoPoint":{"lat":12.97194,"lon":77.59369}},{"facility":"Novo Nordisk Investigational Site","city":"Bangalore","state":"Karnataka","zip":"560002","country":"India","geoPoint":{"lat":12.97194,"lon":77.59369}},{"facility":"Novo Nordisk Investigational Site","city":"Bangalore","state":"Karnataka","zip":"560054","country":"India","geoPoint":{"lat":12.97194,"lon":77.59369}},{"facility":"Novo Nordisk Investigational Site","city":"Mysore","state":"Karnataka","zip":"570001","country":"India","geoPoint":{"lat":12.29791,"lon":76.63925}},{"facility":"Novo Nordisk Investigational Site","city":"Indore","state":"Madhya Pradesh","zip":"452008","country":"India","geoPoint":{"lat":22.71792,"lon":75.8333}},{"facility":"Novo Nordisk Investigational Site","city":"Nagpur","state":"Maharashtra","zip":"440003","country":"India","geoPoint":{"lat":21.14631,"lon":79.08491}},{"facility":"Novo Nordisk Investigational Site","city":"Pune","state":"Maharashtra","zip":"411001","country":"India","geoPoint":{"lat":18.51957,"lon":73.85535}},{"facility":"Novo Nordisk Investigational Site","city":"Pune","state":"Maharashtra","zip":"411004","country":"India","geoPoint":{"lat":18.51957,"lon":73.85535}},{"facility":"Novo Nordisk Investigational Site","city":"Pune","state":"Maharashtra","zip":"411013","country":"India","geoPoint":{"lat":18.51957,"lon":73.85535}},{"facility":"Novo Nordisk Investigational Site","city":"Hyderabad","state":"Telangana","zip":"500033","country":"India","geoPoint":{"lat":17.38405,"lon":78.45636}},{"facility":"Novo Nordisk Investigational Site","city":"Lucknow","state":"Uttar Pradesh","zip":"226005","country":"India","geoPoint":{"lat":26.83928,"lon":80.92313}},{"facility":"Novo Nordisk Investigational Site","city":"Noida","state":"Uttar Pradesh","zip":"201301","country":"India","geoPoint":{"lat":28.58,"lon":77.33}},{"facility":"Novo Nordisk Investigational Site","city":"Kolkata","state":"West Bengal","zip":"700027","country":"India","geoPoint":{"lat":22.56263,"lon":88.36304}},{"facility":"Novo Nordisk Investigational Site","city":"Kolkata","state":"West Bengal","zip":"700054","country":"India","geoPoint":{"lat":22.56263,"lon":88.36304}},{"facility":"Novo Nordisk Investigational Site","city":"Hubli","zip":"580022","country":"India","geoPoint":{"lat":18.6429,"lon":76.21599}},{"facility":"Novo Nordisk Investigational Site","city":"Ludhiana","zip":"141001","country":"India","geoPoint":{"lat":30.91204,"lon":75.85379}},{"facility":"Novo Nordisk Investigational Site","city":"Riga","zip":"LV1011","country":"Latvia","geoPoint":{"lat":56.946,"lon":24.10589}},{"facility":"Novo Nordisk Investigational Site","city":"Riga","zip":"LV1057","country":"Latvia","geoPoint":{"lat":56.946,"lon":24.10589}},{"facility":"Novo Nordisk Investigational Site","city":"Tukums","zip":"LV3101","country":"Latvia","geoPoint":{"lat":56.96764,"lon":23.15554}},{"facility":"Novo Nordisk Investigational Site","city":"Beirut","country":"Lebanon","geoPoint":{"lat":33.89332,"lon":35.50157}},{"facility":"Novo Nordisk Investigational Site","city":"Byblos","country":"Lebanon","geoPoint":{"lat":34.12111,"lon":35.64806}},{"facility":"Novo Nordisk Investigational Site","city":"El Achrafiyé","country":"Lebanon","geoPoint":{"lat":33.886,"lon":35.51962}},{"facility":"Novo Nordisk Investigational Site","city":"Hazmiyeh","country":"Lebanon","geoPoint":{"lat":33.85534,"lon":35.53589}},{"facility":"Novo Nordisk Investigational Site","city":"Toa Baja","zip":"00949","country":"Puerto Rico","geoPoint":{"lat":18.44384,"lon":-66.25961}},{"facility":"Novo Nordisk Investigational Site","city":"Trujillo Alto","zip":"00976","country":"Puerto Rico","geoPoint":{"lat":18.35467,"lon":-66.00739}},{"facility":"Novo Nordisk Investigational Site","city":"Dzerzhinskiy","zip":"140091","country":"Russia","geoPoint":{"lat":55.62868,"lon":37.8443}},{"facility":"Novo Nordisk Investigational Site","city":"Moscow","zip":"101990","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"Novo Nordisk Investigational Site","city":"Moscow","zip":"121293","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"Novo Nordisk Investigational Site","city":"Moscow","zip":"125315","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"Novo Nordisk Investigational Site","city":"Saint Petersburg","zip":"197762","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Novo Nordisk Investigational Site","city":"Belgrade","zip":"11000","country":"Serbia","geoPoint":{"lat":44.80401,"lon":20.46513}},{"facility":"Novo Nordisk Investigational Site","city":"Kragujevac","zip":"34000","country":"Serbia","geoPoint":{"lat":44.01667,"lon":20.91667}},{"facility":"Novo Nordisk Investigational Site","city":"Niš","zip":"18000","country":"Serbia","geoPoint":{"lat":43.32472,"lon":21.90333}},{"facility":"Novo Nordisk Investigational Site","city":"Novi Sad","zip":"21000","country":"Serbia","geoPoint":{"lat":45.25167,"lon":19.83694}},{"facility":"Novo Nordisk Investigational Site","city":"Adapazarı","zip":"54290","country":"Turkey (Türkiye)","geoPoint":{"lat":40.78056,"lon":30.40333}},{"facility":"Novo Nordisk Investigational Site","city":"Istanbul","zip":"34130","country":"Turkey (Türkiye)","geoPoint":{"lat":41.01384,"lon":28.94966}},{"facility":"Novo Nordisk Investigational Site","city":"Istanbul","zip":"34722","country":"Turkey (Türkiye)","geoPoint":{"lat":41.01384,"lon":28.94966}},{"facility":"Novo Nordisk Investigational Site","city":"Istanbul","zip":"34890","country":"Turkey (Türkiye)","geoPoint":{"lat":41.01384,"lon":28.94966}}]},"referencesModule":{"references":[{"pmid":"30828917","type":"BACKGROUND","citation":"Unger J, Allison DC, Carlton M, Lakkole K, Lowe D, Murphy G, Panda JK, Sargin M, Kaltoft M, Treppendahl MB, Zoghbi M; LIRA-PRIME global panel. Trial design and baseline data for LIRA-PRIME: A randomized trial investigating the efficacy of liraglutide in controlling glycaemia in type 2 diabetes in a primary care setting. Diabetes Obes Metab. 2019 Jul;21(7):1543-1550. doi: 10.1111/dom.13682. Epub 2019 Mar 26."},{"pmid":"39963952","type":"DERIVED","citation":"Natale P, Green SC, Tunnicliffe DJ, Pellegrino G, Toyama T, Strippoli GF. Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes. Cochrane Database Syst Rev. 2025 Feb 18;2(2):CD015849. doi: 10.1002/14651858.CD015849.pub2."}],"seeAlsoLinks":[{"label":"Clinical Trials at Novo Nordisk","url":"http://novonordisk-trials.com"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"According to the Novo Nordisk disclosure commitment on novonordisk-trials.com"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Participants were randomised in a 1:1 manner to receive either liraglutide or an oral antidiabetic drug (OAD) both as add-on to background therapy with metformin.","recruitmentDetails":"The trial was conducted at 219 sites in Canada (11), Colombia (3), India (16), Latvia (2), Lebanon (4), Russian Federation (5), Serbia (6), Turkey (4) and the United States (168).","groups":[{"id":"FG000","title":"Liraglutide 1.8 mg","description":"Participants were to receive a subcutaneous injection of liraglutide once daily. Participants received 0.6 milligrams (mg) liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the dose of 1.8 mg was reached. The treatment period was 104 weeks."},{"id":"FG001","title":"Oral Antidiabetic Drug","description":"Participants were to receive one selected OAD. The following OADs were allowed: alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, meglitinides, sodium-glucose co-transporter-2 (SGLT-2) inhibitors, sulfonylureas or thiazolidinediones. The treatment period was 104 weeks."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"996"},{"groupId":"FG001","numSubjects":"995"}]},{"type":"Treated","achievements":[{"groupId":"FG000","numSubjects":"980"},{"groupId":"FG001","numSubjects":"984"}]},{"type":"Full Analysis Set (FAS)","achievements":[{"groupId":"FG000","numSubjects":"996"},{"groupId":"FG001","numSubjects":"995"}]},{"type":"Safety Analysis Set (SAS)","achievements":[{"groupId":"FG000","numSubjects":"980"},{"groupId":"FG001","numSubjects":"984"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"446"},{"groupId":"FG001","numSubjects":"362"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"550"},{"groupId":"FG001","numSubjects":"633"}]}],"dropWithdraws":[{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"4"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"8"}]},{"type":"Inadequate glycaemic control","reasons":[{"groupId":"FG000","numSubjects":"368"},{"groupId":"FG001","numSubjects":"473"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"79"},{"groupId":"FG001","numSubjects":"41"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"23"},{"groupId":"FG001","numSubjects":"30"}]},{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"13"}]},{"type":"Pregnancy","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"45"},{"groupId":"FG001","numSubjects":"42"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"25"},{"groupId":"FG001","numSubjects":"21"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"FAS included all randomised participants.","groups":[{"id":"BG000","title":"Liraglutide 1.8 mg","description":"Participants were to receive a subcutaneous injection of liraglutide once daily. Participants received 0.6 milligrams (mg) liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the dose of 1.8 mg was reached. The treatment period was 104 weeks."},{"id":"BG001","title":"Oral Antidiabetic Drug","description":"Participants were to receive one selected OAD. The following OADs were allowed: alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, meglitinides, sodium-glucose co-transporter-2 (SGLT-2) inhibitors, sulfonylureas or thiazolidinediones. The treatment period was 104 weeks."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"996"},{"groupId":"BG001","value":"995"},{"groupId":"BG002","value":"1991"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"57.6","spread":"11.0"},{"groupId":"BG001","value":"57.1","spread":"10.7"},{"groupId":"BG002","value":"57.4","spread":"10.8"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"476"},{"groupId":"BG001","value":"471"},{"groupId":"BG002","value":"947"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"520"},{"groupId":"BG001","value":"524"},{"groupId":"BG002","value":"1044"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"176"},{"groupId":"BG001","value":"189"},{"groupId":"BG002","value":"365"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"820"},{"groupId":"BG001","value":"806"},{"groupId":"BG002","value":"1626"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Race/Ethnicity, Customized","description":"Race","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"9"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"149"},{"groupId":"BG001","value":"141"},{"groupId":"BG002","value":"290"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"101"},{"groupId":"BG001","value":"106"},{"groupId":"BG002","value":"207"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"5"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"724"},{"groupId":"BG001","value":"714"},{"groupId":"BG002","value":"1438"}]},{"title":"Other","measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"42"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Time to Inadequate Glycaemic Control","description":"Inadequate glycaemic control was defined as glycosylated haemoglobin (HbA1c) of 7.0% (53 mmol/mol) or greater at two consecutive visits after the first 26 weeks of treatment and up to 104 weeks. 25%, median (50%) and 75% percentiles for the cumulative distribution function, are obtained from the Kaplan-Meier survival function. HbA1c was recorded at weeks 38, 52, 65, 78, 91 and 104.","populationDescription":"FAS included all randomised participants. Overall number of participants analyzed=participants with available data.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"Weeks","timeFrame":"Weeks 26-104","groups":[{"id":"OG000","title":"Liraglutide 1.8 mg","description":"Participants were to receive a subcutaneous injection of liraglutide once daily. Participants received 0.6 milligrams (mg) liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the dose of 1.8 mg was reached. The treatment period was 104 weeks."},{"id":"OG001","title":"Oral Antidiabetic Drug","description":"Participants were to receive one selected OAD. The following OADs were allowed: alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, meglitinides, sodium-glucose co-transporter-2 (SGLT-2) inhibitors, sulfonylureas or thiazolidinediones. The treatment period was 104 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"416"},{"groupId":"OG001","value":"547"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"108.9","lowerLimit":"37.7","upperLimit":"NA","comment":"The 75 percentile data was not available as the proportion was not reached within study period."},{"groupId":"OG001","value":"64.9","lowerLimit":"35.4","upperLimit":"107.4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Test for no treatment difference is based on using a generalised log-rank test for interval censored failure time data.","nonInferiorityType":"SUPERIORITY","pValue":"<.0001","statisticalMethod":"Log Rank"}]},{"type":"SECONDARY","title":"Time to Premature Treatment Discontinuation (for Any Reason Including Inadequate Glycaemic Control)","description":"The time to premature treatment discontinuation (for any reason including inadequate glycaemic control) was analysed and presented using the generalised log rank test. 25%, median (50%) and 75% percentiles for the cumulative distribution function, are obtained from the Kaplan-Meier survival function.","populationDescription":"FAS included all randomised participants. Overall number of participants analyzed=participants with available data.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"Weeks","timeFrame":"Weeks 0-104","groups":[{"id":"OG000","title":"Liraglutide 1.8 mg","description":"Participants were to receive a subcutaneous injection of liraglutide once daily. Participants received 0.6 milligrams (mg) liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the dose of 1.8 mg was reached. The treatment period was 104 weeks."},{"id":"OG001","title":"Oral Antidiabetic Drug","description":"Participants were to receive one selected OAD. The following OADs were allowed: alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, meglitinides, sodium-glucose co-transporter-2 (SGLT-2) inhibitors, sulfonylureas or thiazolidinediones. The treatment period was 104 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"532"},{"groupId":"OG001","value":"624"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.4","lowerLimit":"35.7","upperLimit":"NA","comment":"The 75 percentile data was not available as the proportion was not reached within study period."},{"groupId":"OG001","value":"52.3","lowerLimit":"35.1","upperLimit":"NA","comment":"The 75 percentile data was not available as the proportion was not reached within study period."}]}]}]},{"type":"SECONDARY","title":"Change in HbA1c","description":"Change from baseline (week 0) in HbA1c at week 104 or at premature treatment discontinuation is presented.","populationDescription":"Overall number of participants analyzed=FAS included all randomised participants. Number analyzed=participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Percentage point of HbA1c","timeFrame":"Week 0, week 104/premature treatment discontinuation","groups":[{"id":"OG000","title":"Liraglutide 1.8 mg","description":"Participants were to receive a subcutaneous injection of liraglutide once daily. Participants received 0.6 milligrams (mg) liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the dose of 1.8 mg was reached. The treatment period was 104 weeks."},{"id":"OG001","title":"Oral Antidiabetic Drug","description":"Participants were to receive one selected OAD. The following OADs were allowed: alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, meglitinides, sodium-glucose co-transporter-2 (SGLT-2) inhibitors, sulfonylureas or thiazolidinediones. The treatment period was 104 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"996"},{"groupId":"OG001","value":"995"}]}],"classes":[{"title":"Change at week 104","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"404"},{"groupId":"OG001","value":"327"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"1.06"},{"groupId":"OG001","value":"-1.1","spread":"1.04"}]}]},{"title":"Change at premature treatment discontinuation","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"1.03"},{"groupId":"OG001","value":"-0.2","spread":"1.56"}]}]}]},{"type":"SECONDARY","title":"Participants Who Achieve HbA1c ≤6.5% (Yes/No)","description":"Participants who achieved HbA1c ≤6.5% (yes/no) is presented.","populationDescription":"FAS included all randomised participants.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Week 104/Premature treatment discontinuation","groups":[{"id":"OG000","title":"Liraglutide 1.8 mg","description":"Participants were to receive a subcutaneous injection of liraglutide once daily. Participants received 0.6 milligrams (mg) liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the dose of 1.8 mg was reached. The treatment period was 104 weeks."},{"id":"OG001","title":"Oral Antidiabetic Drug","description":"Participants were to receive one selected OAD. The following OADs were allowed: alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, meglitinides, sodium-glucose co-transporter-2 (SGLT-2) inhibitors, sulfonylureas or thiazolidinediones. The treatment period was 104 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"996"},{"groupId":"OG001","value":"995"}]}],"classes":[{"categories":[{"title":"Yes","measurements":[{"groupId":"OG000","value":"255"},{"groupId":"OG001","value":"162"}]},{"title":"No","measurements":[{"groupId":"OG000","value":"741"},{"groupId":"OG001","value":"833"}]}]}]},{"type":"SECONDARY","title":"Participants Who Achieve HbA1c ≤7.0% Without Weight Gain","description":"Participants who achieved HbA1c ≤7.0% without weight gain (yes/no) is presented.","populationDescription":"FAS included all randomised participants.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Week 104/Premature treatment discontinuation","groups":[{"id":"OG000","title":"Liraglutide 1.8 mg","description":"Participants were to receive a subcutaneous injection of liraglutide once daily. Participants received 0.6 milligrams (mg) liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the dose of 1.8 mg was reached. The treatment period was 104 weeks."},{"id":"OG001","title":"Oral Antidiabetic Drug","description":"Participants were to receive one selected OAD. The following OADs were allowed: alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, meglitinides, sodium-glucose co-transporter-2 (SGLT-2) inhibitors, sulfonylureas or thiazolidinediones. The treatment period was 104 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"996"},{"groupId":"OG001","value":"995"}]}],"classes":[{"categories":[{"title":"Yes","measurements":[{"groupId":"OG000","value":"329"},{"groupId":"OG001","value":"234"}]},{"title":"No","measurements":[{"groupId":"OG000","value":"667"},{"groupId":"OG001","value":"761"}]}]}]},{"type":"SECONDARY","title":"Participants Who Achieve HbA1c ≤7.0% Without Treatment Emergent Severe Hypoglycaemic Episodes or BG Confirmed Symptomatic Hypoglycaemic Episodes","description":"Severe or blood glucose (BG) confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \\<3.1 millimoles per liter (mmol/L) with symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than the day after the last day on trial product. Participants who achieved HbA1c ≤7.0% without treatment emergent severe hypoglycaemic episodes or BG confirmed symptomatic hypoglycaemic episodes (yes/no) is presented.","populationDescription":"FAS included all randomised participants.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Week 104/Premature treatment discontinuation","groups":[{"id":"OG000","title":"Liraglutide 1.8 mg","description":"Participants were to receive a subcutaneous injection of liraglutide once daily. Participants received 0.6 milligrams (mg) liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the dose of 1.8 mg was reached. The treatment period was 104 weeks."},{"id":"OG001","title":"Oral Antidiabetic Drug","description":"Participants were to receive one selected OAD. The following OADs were allowed: alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, meglitinides, sodium-glucose co-transporter-2 (SGLT-2) inhibitors, sulfonylureas or thiazolidinediones. The treatment period was 104 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"996"},{"groupId":"OG001","value":"995"}]}],"classes":[{"categories":[{"title":"Yes","measurements":[{"groupId":"OG000","value":"388"},{"groupId":"OG001","value":"292"}]},{"title":"No","measurements":[{"groupId":"OG000","value":"608"},{"groupId":"OG001","value":"703"}]}]}]},{"type":"SECONDARY","title":"Participants Who Achieve HbA1c ≤7.0% Without Weight Gain and no Treatment Emergent Severe Hypoglycaemic Episodes or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes","description":"Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \\<3.1 mmol/L with symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than the day after the last day on trial product. Participants who achieved HbA1c ≤7.0% without weight gain and no treatment emergent severe hypoglycaemic episodes or BG confirmed symptomatic hypoglycaemic episodes (yes/no) is presented.","populationDescription":"FAS included all randomised participants.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Week 104/Premature treatment discontinuation","groups":[{"id":"OG000","title":"Liraglutide 1.8 mg","description":"Participants were to receive a subcutaneous injection of liraglutide once daily. Participants received 0.6 milligrams (mg) liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the dose of 1.8 mg was reached. The treatment period was 104 weeks."},{"id":"OG001","title":"Oral Antidiabetic Drug","description":"Participants were to receive one selected OAD. The following OADs were allowed: alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, meglitinides, sodium-glucose co-transporter-2 (SGLT-2) inhibitors, sulfonylureas or thiazolidinediones. The treatment period was 104 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"996"},{"groupId":"OG001","value":"995"}]}],"classes":[{"categories":[{"title":"Yes","measurements":[{"groupId":"OG000","value":"320"},{"groupId":"OG001","value":"227"}]},{"title":"No","measurements":[{"groupId":"OG000","value":"676"},{"groupId":"OG001","value":"768"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose (FPG)","description":"Change from baseline (week 0) in FPG at week 104 or at premature treatment discontinuation is presented.","populationDescription":"Overall number of participants analyzed=FAS included all randomised participants. Number analyzed=participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Millimoles per liter (mmol/L)","timeFrame":"Week 0, week 104/premature treatment discontinuation","groups":[{"id":"OG000","title":"Liraglutide 1.8 mg","description":"Participants were to receive a subcutaneous injection of liraglutide once daily. Participants received 0.6 milligrams (mg) liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the dose of 1.8 mg was reached. The treatment period was 104 weeks."},{"id":"OG001","title":"Oral Antidiabetic Drug","description":"Participants were to receive one selected OAD. The following OADs were allowed: alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, meglitinides, sodium-glucose co-transporter-2 (SGLT-2) inhibitors, sulfonylureas or thiazolidinediones. The treatment period was 104 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"996"},{"groupId":"OG001","value":"995"}]}],"classes":[{"title":"Change at week 104","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"418"},{"groupId":"OG001","value":"346"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","spread":"2.65"},{"groupId":"OG001","value":"-1.2","spread":"2.46"}]}]},{"title":"Change at premature treatment discontinuation","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"103"},{"groupId":"OG001","value":"78"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"2.91"},{"groupId":"OG001","value":"-0.6","spread":"3.76"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight","description":"Change from baseline (week 0) in body weight at week 104 or at premature treatment discontinuation is presented.","populationDescription":"Overall number of participants analyzed=FAS included all randomised participants. Number analyzed=participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Kilogram (Kg)","timeFrame":"Week 0, week 104/premature treatment discontinuation","groups":[{"id":"OG000","title":"Liraglutide 1.8 mg","description":"Participants were to receive a subcutaneous injection of liraglutide once daily. Participants received 0.6 milligrams (mg) liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the dose of 1.8 mg was reached. The treatment period was 104 weeks."},{"id":"OG001","title":"Oral Antidiabetic Drug","description":"Participants were to receive one selected OAD. The following OADs were allowed: alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, meglitinides, sodium-glucose co-transporter-2 (SGLT-2) inhibitors, sulfonylureas or thiazolidinediones. The treatment period was 104 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"996"},{"groupId":"OG001","value":"995"}]}],"classes":[{"title":"Change at week 104","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"427"},{"groupId":"OG001","value":"349"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.8","spread":"6.38"},{"groupId":"OG001","value":"-3.5","spread":"6.19"}]}]},{"title":"Change at premature treatment discontinuation","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"86"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.9","spread":"3.74"},{"groupId":"OG001","value":"-2.2","spread":"4.93"}]}]}]},{"type":"SECONDARY","title":"Change in Body Mass Index (BMI)","description":"Change from baseline (week 0) in BMI at week 104 or at premature treatment discontinuation is presented.","populationDescription":"Overall number of participants analyzed=FAS included all randomised participants. Number analyzed=participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Kilograms per square meter (kg/m^2)","timeFrame":"Week 0, week 104/premature treatment discontinuation","groups":[{"id":"OG000","title":"Liraglutide 1.8 mg","description":"Participants were to receive a subcutaneous injection of liraglutide once daily. Participants received 0.6 milligrams (mg) liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the dose of 1.8 mg was reached. The treatment period was 104 weeks."},{"id":"OG001","title":"Oral Antidiabetic Drug","description":"Participants were to receive one selected OAD. The following OADs were allowed: alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, meglitinides, sodium-glucose co-transporter-2 (SGLT-2) inhibitors, sulfonylureas or thiazolidinediones. The treatment period was 104 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"996"},{"groupId":"OG001","value":"995"}]}],"classes":[{"title":"Change at week 104","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"427"},{"groupId":"OG001","value":"349"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"2.26"},{"groupId":"OG001","value":"-1.2","spread":"2.14"}]}]},{"title":"Change at premature treatment discontinuation","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"86"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"1.33"},{"groupId":"OG001","value":"-0.8","spread":"1.71"}]}]}]},{"type":"SECONDARY","title":"Change in Blood Pressure (Systolic and Diastolic Blood Pressure)","description":"Change from baseline (week 0) in systolic and diastolic blood pressure at week 104 or at premature treatment discontinuation is presented.","populationDescription":"Overall number of participants analyzed=FAS included all randomised participants. Number analyzed=participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Millimeters of mercury (mmHg)","timeFrame":"Week 0, week 104/premature treatment discontinuation","groups":[{"id":"OG000","title":"Liraglutide 1.8 mg","description":"Participants were to receive a subcutaneous injection of liraglutide once daily. Participants received 0.6 milligrams (mg) liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the dose of 1.8 mg was reached. The treatment period was 104 weeks."},{"id":"OG001","title":"Oral Antidiabetic Drug","description":"Participants were to receive one selected OAD. The following OADs were allowed: alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, meglitinides, sodium-glucose co-transporter-2 (SGLT-2) inhibitors, sulfonylureas or thiazolidinediones. The treatment period was 104 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"996"},{"groupId":"OG001","value":"995"}]}],"classes":[{"title":"SBP: Change at week 104","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"429"},{"groupId":"OG001","value":"350"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":"15.09"},{"groupId":"OG001","value":"-1.1","spread":"15.11"}]}]},{"title":"SBP: Change at premature treatment discontinuation","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"117"},{"groupId":"OG001","value":"87"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.8","spread":"15.99"},{"groupId":"OG001","value":"-2.9","spread":"15.23"}]}]},{"title":"DBP: Change at week 104","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"429"},{"groupId":"OG001","value":"351"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"9.51"},{"groupId":"OG001","value":"-0.6","spread":"9.54"}]}]},{"title":"DBP: Change at premature treatment discontinuation","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"117"},{"groupId":"OG001","value":"87"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"11.27"},{"groupId":"OG001","value":"0.2","spread":"9.69"}]}]}]},{"type":"SECONDARY","title":"Number of Severe Hypoglycaemic Episodes","description":"Severe hypoglycaemic episodes were defined as episodes that required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Number of severe hypoglycaemic episodes that occured during weeks 0-104 are presented.","populationDescription":"Safety analysis set (SAS) included all participants exposed to at least one dose of trial product.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Episodes","timeFrame":"Weeks 0-104","groups":[{"id":"OG000","title":"Liraglutide 1.8 mg","description":"Participants were to receive a subcutaneous injection of liraglutide once daily. Participants received 0.6 milligrams (mg) liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the dose of 1.8 mg was reached. The treatment period was 104 weeks."},{"id":"OG001","title":"Oral Antidiabetic Drug","description":"Participants were to receive one selected OAD. The following OADs were allowed: alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, meglitinides, sodium-glucose co-transporter-2 (SGLT-2) inhibitors, sulfonylureas or thiazolidinediones. The treatment period was 104 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"980"},{"groupId":"OG001","value":"984"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"52"}]}]}]},{"type":"SECONDARY","title":"Number of Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes","description":"Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \\<3.1 mmol/L with symptoms consistent with hypoglycaemia. Number of severe or BG confirmed symptomatic hypoglycaemic episodes that occured during weeks 0-104 are presented.","populationDescription":"SAS included all participants exposed to at least one dose of trial product.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Episodes","timeFrame":"Weeks 0-104","groups":[{"id":"OG000","title":"Liraglutide 1.8 mg","description":"Participants were to receive a subcutaneous injection of liraglutide once daily. Participants received 0.6 milligrams (mg) liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the dose of 1.8 mg was reached. The treatment period was 104 weeks."},{"id":"OG001","title":"Oral Antidiabetic Drug","description":"Participants were to receive one selected OAD. The following OADs were allowed: alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, meglitinides, sodium-glucose co-transporter-2 (SGLT-2) inhibitors, sulfonylureas or thiazolidinediones. The treatment period was 104 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"980"},{"groupId":"OG001","value":"984"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"44"}]}]}]},{"type":"SECONDARY","title":"Number of Documented Symptomatic Hypoglycaemic Episodes (ADA)","description":"Documented symptomatic hypoglycaemic were defined as episodes with typical symptoms of hypoglycaemia accompanied by measure plasma glucose concentration \\<= 3.9 mmol/L. Number of documented symptomatic hypoglycaemic episodes that occured during the weeks 0-104 are presented.","populationDescription":"SAS included all participants exposed to at least one dose of trial product.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Episodes","timeFrame":"Weeks 0-104","groups":[{"id":"OG000","title":"Liraglutide 1.8 mg","description":"Participants were to receive a subcutaneous injection of liraglutide once daily. Participants received 0.6 milligrams (mg) liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the dose of 1.8 mg was reached. The treatment period was 104 weeks."},{"id":"OG001","title":"Oral Antidiabetic Drug","description":"Participants were to receive one selected OAD. The following OADs were allowed: alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, meglitinides, sodium-glucose co-transporter-2 (SGLT-2) inhibitors, sulfonylureas or thiazolidinediones. The treatment period was 104 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"980"},{"groupId":"OG001","value":"984"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"155"}]}]}]},{"type":"SECONDARY","title":"Number of Serious Adverse Events (SAEs)","description":"A serious adverse event (SAE) was defined as any event that resulted in any of the following: death, life-threatening experience, in-patient hospitalisation or prolongation of existing hospitalisation, persistent or significant disability or incapacity, congenital anomaly or birth defect or suspicion of transmission of infectious agents via the trial product. An SAE was considered as treatment emergent if it had an onset or increase in severity on or after the time of first trial product administration and no later than 7 days after the time of last trial product administration. Number of treatment emergent serious adverse events are presented.","populationDescription":"SAS included all participants exposed to at least one dose of trial product.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Events","timeFrame":"Weeks 0-105","groups":[{"id":"OG000","title":"Liraglutide 1.8 mg","description":"Participants were to receive a subcutaneous injection of liraglutide once daily. Participants received 0.6 milligrams (mg) liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the dose of 1.8 mg was reached. The treatment period was 104 weeks."},{"id":"OG001","title":"Oral Antidiabetic Drug","description":"Participants were to receive one selected OAD. The following OADs were allowed: alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, meglitinides, sodium-glucose co-transporter-2 (SGLT-2) inhibitors, sulfonylureas or thiazolidinediones. The treatment period was 104 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"980"},{"groupId":"OG001","value":"984"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"145"},{"groupId":"OG001","value":"140"}]}]}]},{"type":"SECONDARY","title":"Number of AEs Leading to Permanent Discontinuation of Trial Product","description":"An adverse event (AE) was any untoward medical occurrence in a participant who administered a product, and which did not necessarily had a causal relationship with this treatment. An AE was considered as treatment emergent if it had an onset or increase in severity on or after the time of first trial product administration and no later than 7 days after the time of last trial product administration. Number of treatment emergent AEs that led to permanent discontinuation of trial product are presented.","populationDescription":"SAS included all participants exposed to at least one dose of trial product.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Events","timeFrame":"Weeks 0-105","groups":[{"id":"OG000","title":"Liraglutide 1.8 mg","description":"Participants were to receive a subcutaneous injection of liraglutide once daily. Participants received 0.6 milligrams (mg) liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the dose of 1.8 mg was reached. The treatment period was 104 weeks."},{"id":"OG001","title":"Oral Antidiabetic Drug","description":"Participants were to receive one selected OAD. The following OADs were allowed: alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, meglitinides, sodium-glucose co-transporter-2 (SGLT-2) inhibitors, sulfonylureas or thiazolidinediones. The treatment period was 104 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"980"},{"groupId":"OG001","value":"984"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"188"},{"groupId":"OG001","value":"98"}]}]}]},{"type":"SECONDARY","title":"Change in Lipids: HDL Cholesterol, LDL-cholesterol, Total Cholesterol, Triglycerides","description":"Change from baseline (week 0) in high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, total cholesterol (TC) and triglycerides (TG) at week 104 or at premature treatment discontinuation is presented.","populationDescription":"Overall number of participants analyzed=SAS included all participants exposed to at least one dose of trial product. Number analyzed=participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Millimoles per liter (mmol/L)","timeFrame":"Week 0, week 104/premature treatment discontinuation","groups":[{"id":"OG000","title":"Liraglutide 1.8 mg","description":"Participants were to receive a subcutaneous injection of liraglutide once daily. Participants received 0.6 milligrams (mg) liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the dose of 1.8 mg was reached. The treatment period was 104 weeks."},{"id":"OG001","title":"Oral Antidiabetic Drug","description":"Participants were to receive one selected OAD. The following OADs were allowed: alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, meglitinides, sodium-glucose co-transporter-2 (SGLT-2) inhibitors, sulfonylureas or thiazolidinediones. The treatment period was 104 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"980"},{"groupId":"OG001","value":"984"}]}],"classes":[{"title":"HDL: Change at week 104","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"417"},{"groupId":"OG001","value":"339"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.20"},{"groupId":"OG001","value":"0.1","spread":"0.19"}]}]},{"title":"HDL: Change at premature treatment discontinuation","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"80"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"0.17"},{"groupId":"OG001","value":"0.0","spread":"0.20"}]}]},{"title":"LDL: Change at week 104","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"417"},{"groupId":"OG001","value":"339"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.80"},{"groupId":"OG001","value":"0.0","spread":"0.83"}]}]},{"title":"LDL: Change at premature treatment discontinuation","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"80"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.68"},{"groupId":"OG001","value":"-0.1","spread":"0.85"}]}]},{"title":"TC: Change at week 104","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"419"},{"groupId":"OG001","value":"340"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"0.92"},{"groupId":"OG001","value":"0.1","spread":"0.99"}]}]},{"title":"TC: Change at premature treatment discontinuation","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"80"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"0.81"},{"groupId":"OG001","value":"-0.1","spread":"0.96"}]}]},{"title":"TG: Change at week 104","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"418"},{"groupId":"OG001","value":"340"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.95"},{"groupId":"OG001","value":"-0.1","spread":"1.25"}]}]},{"title":"TG: Change at premature treatment discontinuation","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"80"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"1.13"},{"groupId":"OG001","value":"-0.0","spread":"1.30"}]}]}]},{"type":"SECONDARY","title":"Change in Biochemistry- Alanine Aminotransferase (ALAT), Amylase, Aspartate Aminotransferase (ASAT), Lipase","description":"Change from baseline (week 0) in alanine aminotransferase (ALAT), amylase, aspartate aminotransferase (ASAT) and lipase at week 104 or at premature treatment discontinuation is presented.","populationDescription":"Overall number of participants analyzed=SAS included all participants exposed to at least one dose of trial product. Number analyzed=participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Units per liter (U/L)","timeFrame":"Week 0, week 104/premature treatment discontinuation","groups":[{"id":"OG000","title":"Liraglutide 1.8 mg","description":"Participants were to receive a subcutaneous injection of liraglutide once daily. Participants received 0.6 milligrams (mg) liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the dose of 1.8 mg was reached. The treatment period was 104 weeks."},{"id":"OG001","title":"Oral Antidiabetic Drug","description":"Participants were to receive one selected OAD. The following OADs were allowed: alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, meglitinides, sodium-glucose co-transporter-2 (SGLT-2) inhibitors, sulfonylureas or thiazolidinediones. The treatment period was 104 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"980"},{"groupId":"OG001","value":"984"}]}],"classes":[{"title":"ALAT: Week 104","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"408"},{"groupId":"OG001","value":"331"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.6","spread":"17.83"},{"groupId":"OG001","value":"-5.4","spread":"17.13"}]}]},{"title":"ALAT: Premature treatment discontinuation","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.2","spread":"12.44"},{"groupId":"OG001","value":"-3.3","spread":"14.67"}]}]},{"title":"Amylase: Week 104","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"419"},{"groupId":"OG001","value":"340"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.9","spread":"30.93"},{"groupId":"OG001","value":"5.1","spread":"26.30"}]}]},{"title":"Amylase: Premature treatment discontinuation","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"80"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"23.61"},{"groupId":"OG001","value":"2.1","spread":"17.92"}]}]},{"title":"ASAT: Week 104","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"409"},{"groupId":"OG001","value":"337"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","spread":"13.27"},{"groupId":"OG001","value":"-2.3","spread":"11.85"}]}]},{"title":"ASAT: Premature treatment discontinuation","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":"10.76"},{"groupId":"OG001","value":"-0.4","spread":"11.64"}]}]},{"title":"Lipase: Week 104","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"419"},{"groupId":"OG001","value":"340"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.1","spread":"67.69"},{"groupId":"OG001","value":"-0.5","spread":"50.03"}]}]},{"title":"Lipase: Premature treatment discontinuation","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"80"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.4","spread":"32.40"},{"groupId":"OG001","value":"-2.2","spread":"35.79"}]}]}]},{"type":"SECONDARY","title":"Change in Biochemistry- Creatinine, Total Bilirubin","description":"Change from baseline (week 0) in creatinine and total bilirubin (TB) at week 104 or at premature treatment discontinuation is presented.","populationDescription":"Overall number of participants analyzed=SAS included all participants exposed to at least one dose of trial product. Number analyzed=participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Micromoles per liter (umol/L)","timeFrame":"Week 0, week 104/premature treatment discontinuation","groups":[{"id":"OG000","title":"Liraglutide 1.8 mg","description":"Participants were to receive a subcutaneous injection of liraglutide once daily. Participants received 0.6 milligrams (mg) liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the dose of 1.8 mg was reached. The treatment period was 104 weeks."},{"id":"OG001","title":"Oral Antidiabetic Drug","description":"Participants were to receive one selected OAD. The following OADs were allowed: alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, meglitinides, sodium-glucose co-transporter-2 (SGLT-2) inhibitors, sulfonylureas or thiazolidinediones. The treatment period was 104 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"980"},{"groupId":"OG001","value":"984"}]}],"classes":[{"title":"Creatinine: week 104","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"419"},{"groupId":"OG001","value":"340"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"13.37"},{"groupId":"OG001","value":"1.0","spread":"12.86"}]}]},{"title":"Creatinine: premature treatment discontinuation","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"80"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"12.06"},{"groupId":"OG001","value":"2.6","spread":"21.13"}]}]},{"title":"TB: week 104","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"408"},{"groupId":"OG001","value":"331"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"4.47"},{"groupId":"OG001","value":"0.7","spread":"3.80"}]}]},{"title":"TB: premature treatment discontinuation","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"2.78"},{"groupId":"OG001","value":"-0.6","spread":"3.17"}]}]}]},{"type":"SECONDARY","title":"Change in Biochemistry- Estimated Glomerular Filtration Rate (eGFR) Serum","description":"The estimated GFR was derived from serum creatinine using the MDRD (Modification of diet in renal disease) formula. eGFR was measured as milliliter per min per specific surface area (mL/min/SSA).","populationDescription":"Overall number of participants analyzed=SAS included all participants exposed to at least one dose of trial product. Number analyzed=participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mL/min/SSA","timeFrame":"Week 0, week 104/premature treatment discontinuation","groups":[{"id":"OG000","title":"Liraglutide 1.8 mg","description":"Participants were to receive a subcutaneous injection of liraglutide once daily. Participants received 0.6 milligrams (mg) liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the dose of 1.8 mg was reached. The treatment period was 104 weeks."},{"id":"OG001","title":"Oral Antidiabetic Drug","description":"Participants were to receive one selected OAD. The following OADs were allowed: alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, meglitinides, sodium-glucose co-transporter-2 (SGLT-2) inhibitors, sulfonylureas or thiazolidinediones. The treatment period was 104 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"980"},{"groupId":"OG001","value":"984"}]}],"classes":[{"title":"Change at week 104","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"419"},{"groupId":"OG001","value":"340"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.1","spread":"20.33"},{"groupId":"OG001","value":"-1.6","spread":"16.29"}]}]},{"title":"Change at premature treatment discontinuation","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"80"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.0","spread":"12.56"},{"groupId":"OG001","value":"-1.7","spread":"15.01"}]}]}]},{"type":"SECONDARY","title":"Change in Potassium","description":"Change from baseline (week 0) in potassium at week 104 or at premature treatment discontinuation is presented.","populationDescription":"Overall number of participants analyzed=SAS included all participants exposed to at least one dose of trial product. Number analyzed=participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Millimoles per liter (mmol/L)","timeFrame":"Week 0, week 104/premature treatment discontinuation","groups":[{"id":"OG000","title":"Liraglutide 1.8 mg","description":"Participants were to receive a subcutaneous injection of liraglutide once daily. Participants received 0.6 milligrams (mg) liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the dose of 1.8 mg was reached. The treatment period was 104 weeks."},{"id":"OG001","title":"Oral Antidiabetic Drug","description":"Participants were to receive one selected OAD. The following OADs were allowed: alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, meglitinides, sodium-glucose co-transporter-2 (SGLT-2) inhibitors, sulfonylureas or thiazolidinediones. The treatment period was 104 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"980"},{"groupId":"OG001","value":"984"}]}],"classes":[{"title":"Change at week 104","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"419"},{"groupId":"OG001","value":"339"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.60"},{"groupId":"OG001","value":"-0.0","spread":"0.59"}]}]},{"title":"Change at premature treatment discontinuation","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"80"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"0.44"},{"groupId":"OG001","value":"-0.2","spread":"0.71"}]}]}]},{"type":"SECONDARY","title":"Change in Haemoglobin","description":"Change from baseline (week 0) in haemoglobin at week 104 or at premature treatment discontinuation is presented.","populationDescription":"Overall number of participants analyzed=SAS included all participants exposed to at least one dose of trial product. Number analyzed=participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Grams per deciliter (g/dL)","timeFrame":"Week 0, week 104/premature treatment discontinuation","groups":[{"id":"OG000","title":"Liraglutide 1.8 mg","description":"Participants were to receive a subcutaneous injection of liraglutide once daily. Participants received 0.6 milligrams (mg) liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the dose of 1.8 mg was reached. The treatment period was 104 weeks."},{"id":"OG001","title":"Oral Antidiabetic Drug","description":"Participants were to receive one selected OAD. The following OADs were allowed: alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, meglitinides, sodium-glucose co-transporter-2 (SGLT-2) inhibitors, sulfonylureas or thiazolidinediones. The treatment period was 104 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"980"},{"groupId":"OG001","value":"984"}]}],"classes":[{"title":"Change at week 104","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"399"},{"groupId":"OG001","value":"331"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"1.07"},{"groupId":"OG001","value":"-0.0","spread":"1.16"}]}]},{"title":"Change at premature treatment discontinuation","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"76"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.87"},{"groupId":"OG001","value":"-0.3","spread":"1.12"}]}]}]},{"type":"SECONDARY","title":"Change in Pulse","description":"Change from baseline (week 0) in pulse at week 104 or at premature treatment discontinuation is presented.","populationDescription":"Overall number of participants analyzed=SAS included all participants exposed to at least one dose of trial product. Number analyzed=participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Beats per minute (beats/min)","timeFrame":"Week 0, week 104/premature treatment discontinuation","groups":[{"id":"OG000","title":"Liraglutide 1.8 mg","description":"Participants were to receive a subcutaneous injection of liraglutide once daily. Participants received 0.6 milligrams (mg) liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the dose of 1.8 mg was reached. The treatment period was 104 weeks."},{"id":"OG001","title":"Oral Antidiabetic Drug","description":"Participants were to receive one selected OAD. The following OADs were allowed: alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, meglitinides, sodium-glucose co-transporter-2 (SGLT-2) inhibitors, sulfonylureas or thiazolidinediones. The treatment period was 104 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"980"},{"groupId":"OG001","value":"984"}]}],"classes":[{"title":"Change at week 104","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"429"},{"groupId":"OG001","value":"350"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"10.25"},{"groupId":"OG001","value":"-0.6","spread":"10.23"}]}]},{"title":"Change at premature treatment discontinuation","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"115"},{"groupId":"OG001","value":"86"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"9.84"},{"groupId":"OG001","value":"0.9","spread":"10.59"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Weeks 0-105","description":"All presented AEs are TEAEs. A TEAE was defined as an event that had onset date on or after the first day of exposure to trial product and no later than 7 days after the last day of trial product administration. Results are based on the SAS which included all participants exposed to at least one dose of trial product.","eventGroups":[{"id":"EG000","title":"Liraglutide 1.8 mg","description":"Participants were to receive a subcutaneous injection of liraglutide once daily. Participants received 0.6 milligrams (mg) liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the dose of 1.8 mg was reached. The treatment period was 104 weeks.","deathsNumAffected":1,"deathsNumAtRisk":980,"seriousNumAffected":92,"seriousNumAtRisk":980,"otherNumAffected":65,"otherNumAtRisk":980},{"id":"EG001","title":"Oral Antidiabetic Drug","description":"Participants were to receive one selected OAD. The following OADs were allowed: alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, meglitinides, sodium-glucose co-transporter-2 (SGLT-2) inhibitors, sulfonylureas or thiazolidinediones. The treatment period was 104 weeks.","deathsNumAffected":8,"deathsNumAtRisk":984,"seriousNumAffected":81,"seriousNumAtRisk":984,"otherNumAffected":15,"otherNumAtRisk":984}],"seriousEvents":[{"term":"Abdominal pain lower","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":980},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":984}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":980},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":984}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":984}]},{"term":"Angina pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Angina unstable","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Ankle fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Aortic aneurysm","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Arrhythmia supraventricular","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Arterial bypass occlusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Arteriosclerosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Arteriosclerosis coronary artery","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Astrocytoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":980},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":984}]},{"term":"Atrioventricular block second degree","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Bladder transitional cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Blood loss anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Breast cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Calculus urinary","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":980},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":984}]},{"term":"Cardiomyopathy","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Cardiovascular disorder","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Carotid artery stenosis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Cataract","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Cerebral haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":984}]},{"term":"Chronic gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Colitis ischaemic","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Colorectal cancer metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Completed suicide","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Concussion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Conversion disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Coronary artery bypass","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":984}]},{"term":"Coronary artery stenosis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Delusion","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Delusional disorder, unspecified type","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Diabetic ketoacidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Diabetic nephropathy","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Duodenal stenosis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Ectopic pregnancy","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Empty sella syndrome","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"End stage renal disease","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Endometriosis","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Enteritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Erosive duodenitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Erysipelas","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Exophthalmos","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":984}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":984}]},{"term":"Fournier's gangrene","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Gastrectomy","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Gastric bypass","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Gastric ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Gastroenteritis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":984}]},{"term":"Gastrointestinal tract adenoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Gout","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Gun shot wound","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Haemorrhagic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Hepatic cirrhosis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Hepatosplenomegaly","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Hiatus hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":984}]},{"term":"Hip fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Humerus fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Hydronephrosis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":984}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Hypovolaemic shock","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Hypoxic-ischaemic encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Impaired gastric emptying","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Incarcerated hernia","organSystem":"General disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Intervertebral disc degeneration","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Intervertebral disc displacement","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Intervertebral disc protrusion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Invasive ductal breast carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Iron deficiency anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Joint dislocation","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Lactic acidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Lacunar infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Leukocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Ligament rupture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Lower limb fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Lumbar radiculopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Lumbar spinal stenosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Lumbar vertebral fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Lung adenocarcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Lung adenocarcinoma stage IV","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Lung cancer metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Lung neoplasm malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Menorrhagia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Metabolic acidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Metabolic surgery","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Metastases to lung","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Mitral valve incompetence","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":984}]},{"term":"Myocardial ischaemia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":980},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":984}]},{"term":"Obesity","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Oesophageal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Oesophageal varices haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Oesophagitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Osteomyelitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Ovarian adenoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Ovarian cyst","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Pancreatitis acute","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Panic attack","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Papillary thyroid cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Peripheral arterial occlusive disease","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":984}]},{"term":"Peripheral artery occlusion","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Peripheral artery thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Pleural mesothelioma malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":980},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":984}]},{"term":"Pneumonia influenzal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Pneumonia streptococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Portal hypertension","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Postoperative wound infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Prostate cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Psychotic disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Pulmonary hypertension","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Pulmonary sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Pyelonephritis acute","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Rectal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Rectal adenocarcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Rectosigmoid cancer stage III","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Renal colic","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Respiratory distress","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Rib fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Road traffic accident","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Scrotal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":984}]},{"term":"Small intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Spinal compression fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Spinal cord haematoma","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Spinal laminectomy","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Spinal stenosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Subarachnoid haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Tonsillitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Triple negative breast cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Troponin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Ureterolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Urosepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Ventricular fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Vertigo positional","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":980},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":984}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]},{"term":"Wound","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":980},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":984}]}],"otherEvents":[{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":82,"numAffected":65,"numAtRisk":980},{"groupId":"EG001","numEvents":21,"numAffected":15,"numAtRisk":984}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property."},"pointOfContact":{"title":"Clinical Reporting Anchor and Disclosure (1452)","organization":"Novo Nordisk A/S","email":"clinicaltrials@novonordisk.com","phone":"(+1) 866-867-7178"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2020-01-14","uploadDate":"2020-06-16T05:53","filename":"Prot_000.pdf","size":926017},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2020-01-14","uploadDate":"2020-06-16T05:53","filename":"SAP_001.pdf","size":673477}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-09"},"conditionBrowseModule":{"meshes":[{"id":"D003920","term":"Diabetes Mellitus"},{"id":"D003924","term":"Diabetes Mellitus, Type 2"}],"ancestors":[{"id":"D044882","term":"Glucose Metabolism Disorders"},{"id":"D008659","term":"Metabolic Diseases"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D004700","term":"Endocrine System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069450","term":"Liraglutide"},{"id":"D065089","term":"Glycoside Hydrolase Inhibitors"},{"id":"D054873","term":"Dipeptidyl-Peptidase IV Inhibitors"},{"id":"C030516","term":"meglitinide"},{"id":"D000077203","term":"Sodium-Glucose Transporter 2 Inhibitors"},{"id":"D013453","term":"Sulfonylurea Compounds"},{"id":"D045162","term":"Thiazolidinediones"}],"ancestors":[{"id":"D052216","term":"Glucagon-Like Peptide 1"},{"id":"D004763","term":"Glucagon-Like Peptides"},{"id":"D052336","term":"Proglucagon"},{"id":"D005768","term":"Gastrointestinal Hormones"},{"id":"D006728","term":"Hormones"},{"id":"D006730","term":"Hormones, Hormone Substitutes, and Hormone Antagonists"},{"id":"D004791","term":"Enzyme Inhibitors"},{"id":"D045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D020228","term":"Pharmacologic Actions"},{"id":"D020164","term":"Chemical Actions and Uses"},{"id":"D007004","term":"Hypoglycemic Agents"},{"id":"D045505","term":"Physiological Effects of Drugs"},{"id":"D011480","term":"Protease Inhibitors"},{"id":"D014508","term":"Urea"},{"id":"D000577","term":"Amides"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D013450","term":"Sulfones"},{"id":"D013457","term":"Sulfur Compounds"},{"id":"D013844","term":"Thiazoles"},{"id":"D001393","term":"Azoles"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"}]}},"hasResults":true}